IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

BACKGROUND: Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pachynski, Russell K, Morishima, Chihiro, Szmulewitz, Russell, Harshman, Lauren, Appleman, Leonard, Monk, Paul, Bitting, Rhonda L, Kucuk, Omer, Millard, Frederick, Seigne, John D, Fling, Steven P, Maecker, Holden T, Duault, Caroline, Ramchurren, Nirasha, Hess, Bruce, D’Amico, Leonard, Lacroix, Andreanne, Kaiser, Judith C, Morre, Michel, Grégoire, Anne, Cheever, Martin, Yu, Evan Y, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404457/
https://www.ncbi.nlm.nih.gov/pubmed/34452927
http://dx.doi.org/10.1136/jitc-2021-002903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404457/
https://www.ncbi.nlm.nih.gov/pubmed/34452927
http://dx.doi.org/10.1136/jitc-2021-002903

Ejemplares similares